HOME / Notice / News / EN
Dangnyangiwa Saramdeul to Build Pet Immunity-Based Healthcare Business Model with NKCL Bio Group, a Specialized NK Cell Therapy Company Pet life-care platform company Dangnyangiwa Saramdeul announced on the 18th that it has signed a memorandum of understanding (MOU) with immune cell-based biotechnolo...
Expansion of NK cell-based immunotherapy into pet healthcare… advancing a data-driven precision healthcare model NKCL Bio Group Co., Ltd. (CEO: Donghwa Shin), a biotechnology company specializing in immune cell-based technologies, has officially entered the companion animal immune healthcare market....
Linkage between clinical research and manufacturing process begins in earnest… Promote standardization of the entire cell therapy development cycle Han Family Nursing Hospital and NKCL Bio Group have begun building an integrated platform encompassing advanced regenerative medicine clinical research ...
- 9th Research Conference held at Kosin University Gospel Hospital in Busan; discussion on adopting ‘multi-omics’ for mechanism elucidation. Continued efforts to review globally advanced technologies for data-driven efficacy validation - NKCL Bio Group proposes integrated immune monitoring system; ...
Kosin University Gospel Hospital (Hospital Director Choi Jong-soon) and NKCL Bio Group (Chairman Shin Dong-hwa) are set to strengthen competitiveness in the field of advanced regenerative medicine through NK cell-based next-generation immune cell therapy research and clinical cooperation. Kosin Unive...
